ArticleEndocrine2018
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database.
Article in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The prevalence of acromegaly is higher than previously reported: Changes over a three-decade period.Clinical endocrinology · 2022Pooled it
- Comparative effectiveness of endoscopic and microscopic adenoma removal in acromegaly.Frontiers in endocrinology · 2023Trial
- Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.Endocrine reviews · 2026Review
- Changing understanding of acromegaly epidemiology and early mortality risk.The Journal of clinical endocrinology and metabolism · 2026Review
- The changing landscape of acromegaly - an epidemiological perspective.Reviews in endocrine & metabolic disorders · 2024Review
- Machine learning-based algorithms applied to drug prescriptions and other healthcare services in the Sicilian claims database to identify acromegaly as a model for the earlier diagnosis of rare diseases.Scientific reports · 2024Article
- Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs.Journal of endocrinological investigation · 2024Article
- Changes in acromegaly comorbidities, treatment, and outcome over three decades: a nationwide cohort study.Frontiers in endocrinology · 2024Article
- Secondary diabetes mellitus in acromegaly.Endocrine · 2023Review
- Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry.Journal of the ASEAN Federation of Endocrine Societies · 2023Article
- Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases.Scientific reports · 2022Article
- Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length.Pituitary · 2022Article
- Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study.BMC geriatrics · 2021Article
- Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.Frontiers in endocrinology · 2021Article
- Acromegaly in the elderly patients.Endocrine · 2020Review
- Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020Review
- AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.Endocrine connections · 2019Article
- Malaysian Consensus Statement for the Diagnosis and Management of Acromegaly.Journal of the ASEAN Federation of Endocrine Societies · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEpidemiological data are pivotal for the estimation of disease burden in populations.
aimOf the study was to estimate the incidence and prevalence of acromegaly in Italy along with the impact of comorbidities and hospitalization rates as compared to the general population.
methodsRetrospective epidemiological study (from 2000 to 2014) and case control-study. Data were extracted from the Health Search Database (HSD). HSD contains patient records from about 1000 general practitioners (GPs) throughout Italy, covering a population of more than 1 million patients. It includes information about patient demographics and medical data including clinical diagnoses and diagnostic tests.
resultsAt the end of the study period, 74 acromegaly patients (out of 1,066,871 people) were identified, resulting in a prevalence of 6.9 per 100,000 inhabitants [95% CI 5.4-8.5]. Prevalence was higher in females than men (p = 0.004), and showed a statistically significant trend of increase over time (p < 0.0001). Overall, incidence during the study period was 0.31 per 100,000 person-years. Hypertension and type II diabetes mellitus were the comorbidities more frequently associated with acromegaly (31.3 and 14.6%, respectively) and patients were more likely to undergo a high frequency of yearly hospitalization (≥3 accesses/year, p < 0.001) compared to sex-age matched controls.
conclusionsThis epidemiological study on acromegaly carried out using a large GP-based database, documented a disease prevalence of about 7 cases per 100,000 inhabitants. As expected, acromegaly was associated with a number of comorbidities (mainly hypertension and type II diabetes mellitus) and a high rate of patients' hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.